Stockscreener 앱 받기
0.0571
34.44%
-0.03
Bio Path Holdings Inc 주식(BPTH)의 최신 뉴스
Stock List: Research Stocks from Around the World - GuruFocus
Bio-Path Holdings approves Wyoming move and creates new preferred stock class - Investing.com Australia
Bio-Path Holdings, Inc. Announces Domestication to Wyoming and Amendment Creating Series S Preferred Stock - Minichart
[8-K] BIO-PATH HOLDINGS, INC. Reports Material Event | BPTH SEC FilingForm 8-K - Stock Titan
T-Cell Malignancies Clinical Trial Pipeline Accelerates as 75+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Barchart.com
T-Cell Malignancies Clinical Trial Pipeline Accelerates as 75+ - openPR.com
Is Bio Path Holdings Inc. (IBP0) stock a defensive play amid uncertaintyQuarterly Trade Review & Long Hold Capital Preservation Plans - Naître et grandir
[1-Z] BIO-PATH HOLDINGS, INC. SEC Filing - Stock Titan
Bio-Path Holdings issues preferred shares, plans Wyoming move, cancels reverse split By Investing.com - Investing.com South Africa
Bio-Path Holdings issues preferred shares, plans Wyoming move, cancels reverse split - Investing.com Australia
Bio-Path (BPTH) grants CEO affiliate new preferred shares and weighs trial restarts - Stock Titan
BPTHBio-Path Hldgs Inc Latest Stock News & Market Updates - Stock Titan
Head-To-Head Comparison: eFFECTOR Therapeutics (NASDAQ:EFTR) & Bio-Path (NASDAQ:BPTH) - Defense World
Can Bio Path Holdings Inc. (IBP0) stock surprise markets with earningsRate Cut & AI Optimized Trade Strategies - mfd.ru
Marginal Zone Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart.com
Marginal Zone Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working In The Domain Delveinsight - Mena FN
Acute Myeloid Leukemia Market Forecast to 2034: 7MM Opportunity, Strong CAGR, 43,500 Annual Cases, and Pipeline-Driven Growth | DelveInsight - Barchart.com
Acute Myeloid Leukemia Market Forecast to 2034: 7MM - openPR.com
ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer - Yahoo Finance
Antisense Oligonucleotide Therapeutics Clinical Trial - openPR.com
Antisense Oligonucleotide Therapeutics Clinical Trial Pipeline Appears Robust With 70+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart.com
Bio-Path Holdings Q3 2025: Loss of $976K, Shares at $0.07News and Statistics - IndexBox
Bio-Path: Third Quarter Financial Highlights - Bitget
Bio-Path: Q3 Earnings Snapshot - Barchart.com
BPTH: Operational pause, depleted cash, and debt defaults highlight urgent need for new funding - TradingView
BIO-PATH HOLDINGS, INC. SEC 10-Q Report - TradingView
North American Morning Briefing : Dow Futures Stall Ahead of Key Data -2- - marketscreener.com
Tevogen Bio Holdings Inc. (NASDAQ:TVGN): Is Breakeven Near? - Sahm
Top News Today: Stocks Mixed as Energy Rises, Tech Falls - 富途牛牛
Cutaneous T-Cell Lymphoma Clinical Trial Pipeline Gains Momentum: 25+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Barchart.com
North American Morning Briefing : Stock Futures Rise as 2026 Trading Year Begins - MarketScreener
Mondego Bio selects ZE00-0388 as clinical candidate - BioWorld MedTech
What analyst consensus implies for Bio Path Holdings Inc. (IBP0) stockJuly 2025 Rallies & Daily Profit Focused Stock Screening - Улправда
Why analysts recommend Bio Path Holdings Inc. (IBP0) stock2025 Short Interest & Weekly Breakout Watchlists - Улправда
North American Morning Briefing : Stock Futures Up as Investors Bet on Fed Rate Cuts -2- - marketscreener.com
North American Morning Briefing : Dow Futures Climb, Nasdaq Futures Fall -2- - marketscreener.com
Armistice Capital LLC Trims Holdings in UiPath, Inc. $PATH - Defense World
Marginal Zone Lymphoma Treatment Pipeline Shows Strong Momentum as 50+ Pharma Companies in the Race | DelveInsight - The Globe and Mail
Analysts Expect Breakeven For Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Before Long - Yahoo Finance
Critical Survey: NeuroBo Pharmaceuticals (NASDAQ:NRBO) versus Bio-Path (NASDAQ:BPTH) - Defense World
Reviewing Eagle Pharmaceuticals (NASDAQ:EGRX) and Bio-Path (NASDAQ:BPTH) - Defense World
P 500 performance this yearInflation Watch & Technical Pattern Alert System - Newser
Can Bio Path Holdings Inc. (IBP0) stock retain market dominanceJuly 2025 Technicals & Real-Time Volume Triggers - Newser
Acute Myeloid Leukemia Clinical Trial Pipeline Appears - GlobeNewswire
What consensus target says about Bio Path Holdings Inc. (IBP0) stockJuly 2025 Sector Moves & Daily Entry Point Trade Alerts - Newser
Analyzing Aadi Bioscience (NASDAQ:AADI) & Bio-Path (NASDAQ:BPTH) - Defense World
Bio-Path reports positive trial outcomes for cancer treatments - MSN
RNA Interference Pipeline Insights Report 2025: DelveInsight Highlights Emerging Therapeutics Transforming the Future Treatment Landscape - Barchart.com
Axos Financial loses $15M indemnification fight after merger trading fiasco - InvestmentNews
Bio-Path Holdings Inc. (BPTH) Stock Price | Live Quotes & Charts | PINL - StocksToTrade
MSN Money - MSN
0.37%
자본화:
|
볼륨(24시간):